10 new companies to watch – part 2

by Alexey Bersenev on April 24, 2014 · 5 comments

in RegenMed digest

Post to Twitter Send Gmail Post to LinkedIn

5 months ago I’ve picked and brought to your attention a list of new interesting companies. In the last few months, I’ve learned more companies, and today, I’m sharing the new list of 10 with you. As always – please send me your suggestions and I may include them in the next overview. The criteria for this list are the following:

  • Related to stem cell research, regenerative medicine, cell therapy, gene therapy field (therapeutic, tools, reagents, service);
  • New (0-5 years of existence) or relatively new, but under-appreciated and widely unknown;
  • Very unique approach/ new platform

*******************
1. Harvard Apparatus Regenerative Technology
HART is unique, public, clinical-stage company, which commercialized tools for whole organ bioengineering. Right now, HART is manufacturing “scaffolds, bioreactors and other tools for synthetic trachea” and supporting clinical trials. It will be interesting to watch if HART can move from hollow organs to solid organs.

2. CRISPR Therapeutics
Very new startup with stellar team of scientific founders. The company is commercializing new genome editing technology – CRISPR-Cas9 for treatment of genetic diseases. The company recently raised $25M from VC.

3. Regenovo Biotechnology
“Chinese Organovo” – new bioprinting company. They developed their own bioprinter.

4. Cynata Therapeutics
Public, preclinical-stage Australian company, commercializing large scale production of iPS cell-derived mesenchymoangioblasts and MSCs (Cymerus platform) for therapeutic use.

5. TrakCel
Unique provider of cell therapy logistics and cell products tracking. TrakCel platform synchronizes patient info, manufacturing, storage and whole logistics chain.

6. Cyfuse Biomedical
New Japanese bioprinting startup. Cyfuse’s robotic platform “Regenova” is on a market for R&D. Earlier this year, Cyfuse shared their plans to enter clinical trails with bioprinted blood vessels.

7. Cell2B
Portuguese preclinical-stage startup, developing MSC-based therapies. Unlike other “MSC companies”, Cell2B is focused only on immune/ inflammatory conditions. I think, they are representing the 2nd generation of “MSC companies”.

8. Angiocrine Bioscience
Very new startup, spin-off from Weill-Cornell Medical College (Shahin Rafii). The company commercializes “endothelial niche cells” for stem cells and cancer cells expansion in research. Very unique technology with impressive results!

9. Platelet BioGenesis
New unique startup, which utilizes microfluidics chip technology for scalable production of human therapeutic platelets.

10. Biomatrica
Biomatrica develops CellStable platform, which “enable cell-based therapy through ambient biopreservation”. The company offers unique alternative to cell cryopreservation – storage in dry ambient conditions for weeks.

*******************
Disclaimer: This list reflects solely my opinion and sympathy. I have no financial interest in companies, mentioned in this post. This post should not be considered as financial advice.

{ 5 comments… read them below or add one }

Pete Shuster April 25, 2014 at 9:57 am

You missed VODG

Reply

john arnone April 26, 2014 at 4:33 pm

American CryoStem Corporation

Reply

hobbsjustin1 April 26, 2014 at 6:49 pm

Advanced Cell Technology is close to starting a Phase II trial and have arguably the top stem cell scientist in the world. Despite their age you can make the case they are incredibly undervalued and under appreciated and no where near as known as they will be soon?

Reply

Nina April 27, 2014 at 8:01 pm

Bell Biosystems – startup from San Francisco; have devised a unique non-invasive cell tracking technology which has the potential to solve a lot of the problems associated with transplants and monitoring.

Reply

Shaun January 21, 2016 at 2:55 pm

You missed “LifeCell” based in New Jersey.

Reply

Leave a Comment

Previous post:

Next post: